Altman Peter 4

What Happened Peter Altman, President, CEO and a director of BioCardia, acquired a total of 1,000 common shares in two open-market purchases: 600 shares on 2026-04-20 and 400 shares on 2026-04-21. The reported weighted-average price for each day was $1.23, for a combined outlay of $1,230. These were purchases (not sales), which are generally viewed as a more direct indicator of insider buying activity than sales.

Key Details

• Transaction type: Open-market purchases (code P).
• Dates & prices:
  • 2026-04-20 — 600 shares at a weighted average of $1.23 (actual trades ranged $1.22–$1.27) [Footnote F1].
  • 2026-04-21 — 400 shares at a weighted average of $1.23 (actual trades ranged $1.21–$1.24) [Footnote F2].
• Total: 1,000 shares for $1,230.
• Shares owned after the transactions: not specified in the provided filing.
• Filing: Form 4 filed 2026-04-22 for trades on 4/20–4/21; this appears to be filed within the standard two-business-day window.
• Footnotes: The reported prices are weighted averages; the filer offers to provide per-trade details to the SEC or issuer on request.

Context These were small-dollar open-market purchases by the company's CEO (modest in size at $1.2k total), so while purchases can be a positive signal, the low dollar amount limits how much weight investors typically place on them. No options, gifts, or tax-withholding events are involved in these reported transactions.